Valganciclovir – Antiviral Therapy

Valganciclovir is an antiviral medication that acts as an L-valyl ester prodrug of ganciclovir. It was developed to provide high oral bioavailability, making it an effective option for managing severe herpesvirus infections.

The mechanism of action involves the rapid conversion of valganciclovir into ganciclovir by intestinal and hepatic esterases. Inside virus-infected cells, ganciclovir is phosphorylated into its active triphosphate form. This compound competitively inhibits viral DNA polymerase and is incorporated into viral DNA, resulting in the termination of viral DNA synthesis. Valganciclovir exhibits potent activity against cytomegalovirus (CMV), herpes simplex virus types 1 and 2, human herpesvirus types 6, 7, and 8, and Epstein-Barr virus.

The drug is a primary choice for CMV prophylaxis in organ transplant recipients and for the treatment of CMV retinitis in immunocompromised patients.

Wikipedia page
Valganciclovir

Indications

Valganciclovir is indicated for the treatment of adult and pediatric patients in the following cases:

  • CMV Retinitis: treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome (AIDS).
  • CMV Prophylaxis: prevention of CMV disease in solid organ transplant recipients (kidney, heart, pancreas) at high risk for infection.

Dosage and administration

Valganciclovir dosing must be strictly followed due to the risk of toxicity.

  • CMV Retinitis (Induction): 900 mg twice daily for 21 days.
  • Maintenance and Prophylaxis: 900 mg once daily.
  • Administration Rules: tablets should be taken with food to maximize absorption.
  • Renal Impairment: careful dose adjustment is required based on creatinine clearance.
  • Special Handling: tablets should not be broken or crushed due to potential teratogenic and carcinogenic risks.

The use of valganciclovir is restricted in the following conditions:

  • Hypersensitivity: allergy to valganciclovir, ganciclovir, or acyclovir.
  • Hematologic Parameters: severe neutropenia, anemia, or thrombocytopenia.
  • Pregnancy and Lactation: the drug has teratogenic potential; breastfeeding must be discontinued.
  • Renal Failure: end-stage renal disease (creatinine clearance less than 10 mL/min).

Valganciclovir therapy requires regular blood count monitoring:

  • Hematologic: neutropenia, anemia, and thrombocytopenia (bone marrow suppression).
  • Gastrointestinal: diarrhea, nausea, vomiting, and abdominal pain.
  • Nervous System: headache, insomnia, peripheral neuropathy, and rarely, seizures or hallucinations.
  • Infections: increased risk of candidiasis and sepsis.
  • General: fever and fatigue.

Frequently Asked Questions

Valganciclovir is the L-valyl ester of ganciclovir, a "prodrug." After oral administration, it is rapidly converted into ganciclovir by intestinal and hepatic enzymes. This allows for blood concentrations of the active substance that are comparable to those achieved by intravenous administration of ganciclovir itself.
The substance is used for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS, and for the prevention of CMV disease in adult and pediatric solid organ transplant recipients (kidney, heart, pancreas) where the donor is CMV-positive and the recipient is CMV-negative.
Taking valganciclovir with food significantly increases its bioavailability. Food aids in the absorption of the substance into the systemic circulation, ensuring that the necessary therapeutic levels are reached to effectively combat the virus.
Valganciclovir is considered potentially teratogenic and carcinogenic. Tablets should not be broken or crushed. If accidental contact with the powder from a damaged tablet occurs, wash the skin area thoroughly with soap and water; if it gets into the eyes, rinse them extensively with plain water.
Similar to its derivative, valganciclovir can cause severe neutropenia, anemia, and thrombocytopenia (decreased blood cell counts). Patients must undergo frequent complete blood counts and monitor serum creatinine levels, as the dosage must be strictly adjusted in patients with renal impairment.

List of medicines by active substance Valganciclovir

-4%
Valgahet 450 mg Heet Healthcare
View
Heet Healthcare

Valgahet

Valganciclovir
450 mg 60 tablets
6724₴ 7032₴
-33%
Valgan 450 mg Cipla
View
Cipla

Valgan

Valganciclovir
450 mg 4 tablets
967₴ 1450₴
✅ All products loaded (2)

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00